SCHEMBL5485551

SCHEMBL5485551

COC(=O)CCCCOc1ccc2c(c1C)NC(=O)C2(c1ccc(O)cc1)c1ccc(O)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 2/20 0.46
HTT P42858 1/20 0.46
GPR35 Q9HC97 1/20 0.46
GPR55 Q9Y2T6 1/20 0.46
MAPT P10636 1/20 0.37
CNR2 P34972 3/20 0.36
CHRM2 P08172 1/20 0.36
ADORA3 P0DMS8 1/20 0.36
KCNH2 Q12809 1/20 0.36
PPARG P37231 2/20 0.35
ALDH2 P05091 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C19 P33261 1/20 0.34
PDE3B Q13370 3/20 0.33
PDE3A Q14432 3/20 0.33
P2RY12 Q9H244 3/20 0.33
MAOA P21397 1/20 0.33
MAOB P27338 1/20 0.33
PPARA Q07869 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5485519 0.89 CNR1 (0.47) CNR1HTTGPR35GPR55CHRM2
SCHEMBL5485405 0.81 CNR1 (0.48) CNR1HTTGPR35GPR55CNR2
SCHEMBL5474359 0.79 CNR1 (0.58) CNR1HTTGPR35GPR55MAPT
SCHEMBL5483354 0.72 CNR1 (0.49) CNR1HTTGPR35GPR55CHRM2
SCHEMBL5485042 0.71 GPR55 (0.68) CNR1HTTGPR35GPR55MAPT
SCHEMBL5474643 0.69 CNR1 (0.61) CNR1HTTGPR35GPR55MAPT
SCHEMBL5482223 0.69 CNR1 (0.61) CNR1HTTGPR35GPR55MAPT
SCHEMBL5485571 0.68 CNR1 (0.52) CNR1HTTGPR35GPR55MAPT
SCHEMBL5474437 0.66 CNR1 (0.57) CNR1HTTGPR35GPR55MAPT
SCHEMBL3200621 0.66 CNR1 (0.57) CNR1HTTGPR35GPR55MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US claimed
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US disclosed
EP-1734951-A2 DIPHENYL-INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TopoTarget A/S (DK) 2006-12-27 EP disclosed
WO-2005097107-A2 DIPHENYL - INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TOPOTARGET A/S (DK) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer MTOR, RICTOR, CDK4 CNR1 973/4885HTT 1880/4885GPR35 2558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.